US SEC Trading Suspension Halt Orders — June 18, 2026

Received bid price deficiency notice on June 16, 2026; has 180-day cure period through Dec 14, 2026, with possible 180-day extension if it meets other listing standards and notifies intent to cure via reverse split

Received delisting notice on June 18, 2026, after failing to cure bid price deficiency by June 17, 2026, and failing to meet $5M shareholders' equity condition for extension; plans to request hearing to stay delisting

No insider trading activity reported in filing; management's silence on personal transactions may signal lack of conviction in turnaround [NEUTRAL/BEARISH]

No insider trading activity reported in filing; management's decision to request a hearing rather than take immediate curative action suggests uncertainty about regaining compliance [NEUTRAL/BEARISH]

Company is considering options including reverse stock split; no forward guidance or capital allocation actions disclosed, indicating early-stage evaluation

Failed to meet $5M shareholders' equity condition for extension as of June 17, 2026; this financial weakness is a key risk factor for continued listing

Continued trading on Nasdaq during compliance period; no immediate impact on liquidity, but overhang of potential delisting may pressure stock

Request for hearing will automatically stay delisting action at least through panel's written decision; provides temporary relief but no guarantee of long-term compliance

Failed to cure bid price deficiency by deadline AND failed to meet alternative continued listing standards (minimum $2.5M shareholders' equity, $35M market value, or $500K net income); dual failure increases delisting probability

Did not meet $5M shareholders' equity condition for extension as of June 17, 2026; indicates severe financial distress and limited access to capital

Closing bid price below $1.00 for 30 consecutive business days (May 4 to June 15, 2026); no assurance of regaining compliance within 180-day period

Considering reverse stock split to regain compliance; such actions often lead to post-split price declines and can dilute shareholder value

No assurance that Nasdaq panel will grant continued listing; negative outcome could lead to immediate delisting and OTC trading

Both are micro-cap companies with limited trading volume; delisting risk could exacerbate liquidity issues and trigger forced selling by institutional holders

Unlike Algorhythm, Dyadic is not eligible for an automatic 180-day extension due to failure to meet equity condition; timeline for resolution is compressed

If company executes reverse split and regains compliance by Dec 14, 2026, stock could re-rate; currently trading at distressed levels with potential for mean reversion

Stock may be oversold on delisting fears; if Nasdaq panel grants continued listing, shares could rebound significantly; high risk/high reward event-driven play

Company may qualify for additional 180-day extension if it meets other listing standards and notifies intent to cure; provides longer runway for turnaround

If broader market sentiment improves and capital flows return to micro-cap biotech, both companies could attract investment and regain compliance more easily

Stock continues to trade on Nasdaq during compliance period; investors can accumulate at distressed levels before potential catalyst

Hearing request automatically stays delisting; short-term relief rally possible as uncertainty is temporarily removed

Two companies received deficiency/delisting notices in the same week, indicating that many micro-cap firms are struggling to maintain $1.00 bid price amid risk-off sentiment and reduced retail trading activity

Dyadic's failure to meet $5M shareholders' equity condition highlights that micro-cap companies are finding it increasingly difficult to raise capital through equity offerings or retain earnings, a common theme across small-cap biotech

Both companies are considering or have been forced to consider reverse stock splits, a common but often value-destructive mechanism that signals underlying financial weakness and can lead to further price declines post-split

The 180-day compliance period (Algorhythm) and hearing stay (Dyadic) provide temporary windows for companies to regain compliance; investors can exploit these windows for event-driven trades, but timing is critical

The clustering of deficiency notices suggests that institutional and retail investors are rotating out of micro-cap names into larger, more liquid securities, exacerbating price declines and compliance failures

180-day compliance period ends Dec 14, 2026; monitor for reverse stock split announcement or other curative actions; watch for insider buying as signal of management confidence

Nasdaq hearing date to be scheduled; monitor for panel decision on continued listing; watch for any equity raise or business development that could boost shareholders' equity above $5M

Monitor for additional Nasdaq deficiency notices from other micro-cap companies in the same sector; a wave of such notices could signal broader market stress

Q2 2026 earnings report (expected Aug 2026) will provide update on financial position and compliance strategy; watch for any forward guidance on reverse split timing

Any SEC filing regarding hearing outcome or delisting status; watch for Form 8-K disclosing panel decision or transfer to OTC markets

Monitor trading volume and bid-ask spreads; widening spreads and declining volume could signal loss of investor confidence ahead of potential delisting

Watch for any changes in listing standards or enforcement policies that could affect compliance timelines for deficient companies